Vaxil Bio Ltd.
VXLLF
$0.02
-$0.13-85.27%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 78.40K | 31.60K | 23.20K | 26.70K | 48.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.40K | 31.60K | 23.20K | 26.70K | 51.60K |
| Operating Income | -78.40K | -31.60K | -23.20K | -26.70K | -51.60K |
| Income Before Tax | -76.90K | 406.70K | -14.50K | 26.00K | -48.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -76.90K | 406.70K | -14.50K | 26.00K | -48.80K |
| Earnings from Discontinued Operations | -- | 2.20K | -- | 4.30K | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.90K | 408.90K | -14.50K | 30.40K | -48.80K |
| EBIT | -78.40K | -31.60K | -23.20K | -26.70K | -51.60K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | 0.13 | -0.01 | 0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.01 | -0.01 |
| EPS Diluted | -0.02 | 0.13 | -0.01 | 0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.01 | -0.01 |
| Average Basic Shares Outstanding | 3.98M | 3.12M | 2.74M | 2.74M | 2.74M |
| Average Diluted Shares Outstanding | 3.98M | 3.12M | 2.74M | 2.74M | 2.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |